Latest Intelligence on General Business in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Xigris: struggling to overcome its problems

The once lauded drug Xigris is struggling to recover from a series of setbacks, despite existing in a potentially lucrative market with little competition. After disappointing US sales, Xigris has now been launched in Europe. Datamonitor's Michael Randle asks if Eli Lilly can take advantage of its status as the only approved severe sepsis treatment and breathe new life into its sleeping giant.

Published By Datamonitor
15 Nov 2002
Expert View
Expert View

Xigris: Lilly's sepsis flop misses out

Eli Lilly's Xigris sales have proved disappointing, for the year-to-date period ending February 28 2002 sales reached just $14 million, bringing total sales to $35 million since the drug's launch in late November 2001. Industry analysts had predicted sales of between $300 and $500 million in 2002, but this now seems unrealistic, so where did it all go wrong?

Published By Datamonitor
22 Mar 2002
CommentWire
CommentWire

Xenova/QLT: tackling multidrug resistance

UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.

Published By Datamonitor
11 Jul 2002
CommentWire
CommentWire

Wyeth: Prempro linked with dementia

A recent study published in the Journal of the American Medical Association has shown that Wyeth's hormone combination therapy Prempro increases the risk of probable dementia in postmenopausal women aged 65 years or older. Further studies are needed to establish the role of estrogen therapies in the onset of Alzheimer's disease.

Published By Datamonitor
29 May 2003
CommentWire
CommentWire

Wyeth: not SAD about Effexor approval

The expanding versatility of Wyeth's blockbuster Effexor is key to its continued success. Sales should top $2 billion in 2003. However, competition is strong with large players including Pfizer and GlaxoSmithKline battling for a share of the lucrative mood disorders market. Nevertheless, Effexor's advantageous mechanism of action and convenient once-daily dosage will provide the edge over rivals.

Published By Datamonitor
13 Feb 2003
CommentWire
CommentWire

Wyeth: Effexor XR is deemed effective

Wyeth has released the findings of the study, which pooled together results of eight double-blind studies and compared Effexor XR to a leading serotonin selective re-uptake inhibitor. Although the drug's sales should be high it could suffer at the hands of strong competition from Lilly's duloxetine.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Wyeth: a question of consolidation

Revenues at Wyeth have climbed despite declining sales of key products such as Premarin and Prevnar. Litigation expenses continue to impact the bottom line, but a cash injection resulting from the merger of Immunex and Amgen has improved the company's financial situation. There are signs the company could be ripe for consolidation once more.

Published By Datamonitor
30 Jan 2003
CommentWire
CommentWire

Wrigley's: something to chew on

Published By Datamonitor
25 Apr 2001
CommentWire
CommentWire

Wright Medical Group: ready for the public eye

Published By Datamonitor
04 May 2001
CommentWire
CommentWire

WorldCom: nothing to hide

Accounting worries have caused WorldCom's share price to halve over the last month. Although the Q4 results show there is no cause for alarm in the short term, the slow growth rate in the US Internet and long-distance telecoms market (not to mention the questions raised by loans to the CEO) cast a shadow over the company's future prospects.

Published By Datamonitor
08 Feb 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.